论文部分内容阅读
目的:观察细菌溶解产物对慢性阻塞性肺疾病稳定期患者免疫功能的影响。方法:慢性阻塞性肺疾病稳定期患者80例随机分为2组。C组40例给予肠溶阿司匹林100 mg,1次/d,晨起顿服;布地奈德福莫特罗吸入剂80μg,1次/d,疗程1 a。T组40例在C组治疗基础上给予细菌溶解产物(泛福舒)7 mg,1次/d,晨空腹口服,10 d为1个疗程,共3个疗程。同期健康体检者10例为对照组(N组)。观察T,C组治疗1 a内急性发作次数、抗生素使用时间、外周血T淋巴细胞亚群和血清免疫球蛋白及补体的变化,并进行比较。结果:(1)T,C组治疗后急性发作次数、急性发作天数、急性发作期间抗生素使用时间均较治疗前缩短(P<0.05),T组优于C组(P<0.05)。(2)T,C组治疗前外周血CD3+、CD4+水平较N组降低(P<0.05),CD8+水平升高(P<0.05),CD4+/CD8+比值降低(P<0.05);C组治疗后外周血CD3+、CD4+、CD8+、CD4+/CD8+比值与治疗前比较差异均无统计学意义(P>0.05),T组治疗后外周血中CD3+、CD4+、CD8+水平,CD4+/CD8+比值与治疗前比较差异均有统计学意义(P<0.05),2组治疗后各指标比较差异均有统计学意义(P<0.05)。(3)T,C组治疗前外周血IgG,IgA,IgM,C3,C4水平低于N组(P<0.05);C组患者治疗后各指标与治疗前比较差异无统计学意义,T组治疗后外周血中IgG,IgA,IgM,C3,C4水平高于治疗前(P<0.05),2组治疗后各指标比较差异均有统计学意义(P<0.05)。结论:慢性阻塞性肺疾病稳定期患者存在细胞免疫及体液免疫功能紊乱,使用泛福舒治疗可明显改善其免疫功能,减少感染急性发作次数。
Objective: To observe the effect of bacterial lysate on the immune function of patients with chronic obstructive pulmonary disease in stable phase. Methods: Eighty patients with stable chronic obstructive pulmonary disease were randomly divided into two groups. Group C 40 patients given enteric-coated aspirin 100 mg, 1 time / d, morning meal Dayton; budesonide formoterol inhaler 80μg, 1 / d, treatment 1 a. Forty patients in T group were given 7 mg of bacterial lysate (Pan Fu Shu) on the basis of group C treatment once a day for 3 days. In the same period, 10 cases of healthy physical examination as control group (N group). The changes of acute attack, antibiotic use time, peripheral blood T lymphocyte subsets, serum immunoglobulin and complement in T and C groups within 1 year of treatment were observed and compared. Results: (1) The number of acute seizures, the number of acute seizure days and the duration of antibiotics in acute episodes of T and C groups were shorter than those before treatment (P <0.05), and those in T group were better than those in C group (P <0.05). (2) The levels of CD3 + and CD4 + in peripheral blood of T and C groups before treatment were significantly lower than those of N group (P <0.05), CD8 + (P <0.05) and CD4 + / CD8 + There was no significant difference in the ratio of CD3 +, CD4 +, CD8 +, CD4 + / CD8 + between the two groups before treatment (P> 0.05). The levels of CD3 +, CD4 +, CD8 + and CD4 + / CD8 + The differences were statistically significant (P <0.05), the two groups after treatment each index difference was statistically significant (P <0.05). (3) The levels of IgG, IgA, IgM, C3 and C4 in peripheral blood of T and C groups before treatment were lower than those of N group (P <0.05). There was no significant difference in each index between C group and before treatment The levels of IgG, IgA, IgM, C3 and C4 in peripheral blood were higher after treatment than those before treatment (P <0.05). There was significant difference between the two groups after treatment (P <0.05). Conclusion: Patients with chronic obstructive pulmonary disease (COPD) have cellular and humoral immune dysfunction. Treatment with panforts can significantly improve their immune function and reduce the number of acute exacerbations.